PXD027250-1

PXD027250 is an original dataset announced via ProteomeXchange.

Title	Identification of potential of new therapeutic approaches for JAK2 V617F mutant patients
Description	n patients with PMF, excessive secretion of inflammatory cytokines results in fibrotic changes in bone marrow and diminishes the quality of life of the affected patients due to systemic symptoms long-term ruxolitinib therapy may reverse or markedly delay BM fibrosis progression in advanced MF suggests kavasincha 2018
HostingRepository	PRIDE
AnnounceDate	2023-05-18
AnnouncementXML	Submission_2023-05-18_01:50:43.395.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	BethanyGeary
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	iodoacetamide derivatized residue
Instrument	TripleTOF 6600

Revision	Datetime	Status	ChangeLog Entry
0	2021-07-12 08:17:44	ID requested
⏵ 1	2023-05-18 01:50:43	announced
2	2024-10-22 05:45:48	announced	2024-10-22: Updated project metadata.

Dataset with its publication pending

submitter keyword: AML, SWATH, JAK2

BethanyGeary
contact affiliation	Stem Cell and Leukaemia Proteomics Laboratory, Wolfson Molecular Imaging Centre, 27 Palatine Rd, Manchester, M20 3JJ
contact email	bethany.geary@manchester.ac.uk
lab head
BethanyGeary
contact affiliation	University of Manchester
contact email	bethany.geary@manchester.ac.uk
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2023/05/PXD027250

PRIDE project URI

• PRIDE
  1. PXD027250
     1. Label: PRIDE project
     2. Name: Identification of potential of new therapeutic approaches for JAK2 V617F mutant patients